Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT00002281
- Locations
- 🇺🇸
UCLA Med Ctr, Los Angeles, California, United States
An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00002255
- Locations
- 🇺🇸
UCLA Med Ctr, Los Angeles, California, United States
A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 250
- Registration Number
- NCT00002126
- Locations
- 🇺🇸
CARE Ctr / UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Univ Hosp of Cleveland / Case Western Reserve Univ, Cleveland, Ohio, United States
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-01
- Target Recruit Count
- 33
- Registration Number
- NCT00000801
- Locations
- 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, United States
Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-04-17
- Target Recruit Count
- 120
- Registration Number
- NCT00001059
- Locations
- 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Queens Med. Ctr., Honolulu, Hawaii, United States
🇺🇸Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-27
- Target Recruit Count
- 27
- Registration Number
- NCT00000626
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
🇺🇸The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
- Conditions
- Locations
- 🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00001048
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
A Study of Stem Cells and Filgrastim
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 24
- Registration Number
- NCT00001071
- Locations
- 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 10
- Registration Number
- NCT00000899
- Locations
- 🇺🇸
Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Duke Univ Med Ctr, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.